By tracing their trajectory from early breakthroughs to their current prominence, it becomes evident that PSMA PET imaging has evolved into an indispensable tool for diagnosing and staging prostate cancer, particularly in cases of recurrence, offering clinicians unprecedented precision and confidence in patient management. The gene discussed is FOLH1; the disease is prostate cancer.